The Eastern Maine Medical Center's Cancer Program has a fine reputation for attending to the needs of the patient with cancer in Maine's northern and eastern regions. We still need, however, to address a mortality rate higher than the national average in this sparsely populated area of the northeast which has suffered a very poor economy compared to the nation as a whole. This program will continue to be centered around a cohesive multidisciplinary medical team based in a well-established Tumor Clinic and its associated Radiation Therapy Center. Its network of affiliated community cancer clinics has expanded to six since the Community Clinical Oncology Program grant award in 1983, and there are plans to add a seventh. The northernmost part of the state has not had, thus far, the advantage of association with a National Cancer Institute-sponsored program of this type and this deficiency will be addressed by affiliation with a successful network of cancer clinics in Aroostook County which has had, on its own, a solid relationship with the Dana-Farber Cancer Institute for several years. Our goals is to continue increasing accrual to NCI-sponsored cancer treatment protocols and, now that our oncology staff is increased, also to lend our combined expertise to efforts in early detection and prevention of cancer in this underserved area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035406-05
Application #
3557728
Study Section
(SRC)
Project Start
1983-09-26
Project End
1990-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
5
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Eastern Maine Medical Center
Department
Type
DUNS #
071735682
City
Bangor
State
ME
Country
United States
Zip Code
04402
Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2008) Wilms'tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26:4595-602
Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2006) Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24:3904-11
Dressler, Lynn G; Berry, Donald A; Broadwater, Gloria et al. (2005) Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 23:4287-97
Wetzler, Meir; Dodge, Richard K; Mrozek, Krzysztof et al. (2004) Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol 124:275-88
Farag, Sherif S; Ruppert, Amy S; Mrozek, Krzysztof et al. (2004) Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol 25:143-51
Farag, Sherif S; Archer, Kellie J; Mrozek, Krzysztof et al. (2002) Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Int J Oncol 21:1041-51
Stone, R M; Berg, D T; George, S L et al. (2001) Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 98:548-53
Hayes, D F; Yamauchi, H; Broadwater, G et al. (2001) Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703-11